Compare Ascendis Pharma A/S (ASND) vs Roblox Corp (RBLX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Roblox Corp — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Roblox Corp trades at $55.28 (market cap $39.63B). The key difference: Roblox Corp is far larger — about 2.2× Ascendis Pharma A/S's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Roblox Corp nearer its low. Which is the better fit depends on your goals.
| ASND | RBLX | |
|---|---|---|
Market Cap | $17.74B | $39.63B |
Sector | Health | Media |
52-Week High | $277.18 | $141.56 |
52-Week Low | $163.32 | $41.30 |
Enterprise Value | $18.11B | $38.22B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Roblox (RBLX) trades at $55.35, down 1.9% on the day, amid a bullish technical signal and strong analyst support. The stock shows consistent revenue growth, with 2025 revenue reaching $4.89 billion, though it remains unprofitable with a net income margin of -20.69%. Recent earnings have beaten expectations, but the company faces headwinds from a securities class action lawsuit related to age-verification disclosures. Operating cash flow improved to $1.8 billion in 2025, signaling healthy core business operations despite ongoing losses.
The outlook for RBLX is mixed; robust user monetization and revenue growth present upside potential, supported by a consensus price target of $64.07. However, persistent losses, high valuation multiples like a P/B of 91.73, and legal risks weigh on investor confidence. The stock's trajectory hinges on achieving profitability and navigating regulatory scrutiny, making it a high-risk, growth-oriented play.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Roblox Corp
Roblox operates an online video game platform that lets young gamers create, develop, and monetize games (or experiences) for other players. The firm effectively offers its developers a hybrid of a game engine, publishing platform, online hosting and services, marketplace with payment processing, and social network. The platform is a closed garden that Roblox controls, earning revenue in multiple places while benefiting from outsourced game development. Unlike traditional video game publishers, Roblox is more focused on the creation of new tools and monetization techniques for its developers then creating new games or franchises. Roblox is increasingly focused on creating a metaverse that moves beyond games toward experiences like concerts, education, and even business management.
Read more on RBLX →
